Nurix Therapeutics (NASDAQ:NRIX) focuses on discovering, developing, and commercializing small molecule therapies designed to control the body’s protein levels. Leveraging proprietary platforms to manipulate the ubiquitin-proteasome system, their goal is to advance a pipeline of novel therapies targeting critical areas including oncology, inflammation, and immune disorders. Nurix is committed to pushing the boundaries of medical science to create treatments that improve patient outcomes and address unmet medical needs. Through strategic collaborations and internal research, they aim to harness the power of protein degradation to bring innovative medicines from the lab bench to patients in need.